Zymeworks (NYSE:ZYME) inks a collaboration agreement with Pfizer (NYSE:PFE) aimed at advancing a Phase 2 clinical trial evaluating the combination of lead candidate ZW25, Ibrance (palbociclib) and fulvestrant [AstraZeneca’s (NYSE:AZN) Faslodex] in patients with previously-treated locally advanced/metastatic HER2-positive, HR-positive breast cancer.
Zymeworks is sponsoring the study while Pfizer is supplying Ibrance.
ZW25 is is an HER2-targeted bispecific antibody developed with the company’s Azymetric platform.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.